You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Image-guided planning system for skull correction in children with craniosynostos

    SBC: KITWARE INC            Topic: NICHD

    DESCRIPTION (provided by applicant): Craniosynostosis is the premature fusion of cranial sutures and occurs in approximately one in 2000 live births. It results in cranial malformation that can lead to elevated intra-cranial pressure, brain growth impairment, and developmental deficiency. The most common treatment option for craniosynostosis is surgery. Currently, surgical treatment planning of cr ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Sympathetic Nerve Activity Recorded From the Skin and Cardiac Arrhythmias

    SBC: ARRHYTHMOTECH            Topic: NHLBI

    DESCRIPTION (provided by applicant): The broad and long-term objective of this research project is to use, develop and market an instrument for the simultaneous recording of sympathetic nerve activity (SNA) and electrocardiogram (ECG) using electrodes on the skin. This method (neuECG) was discovered in Dr. Chen's research laboratory at the Krannert Institute of Cardiology, and a patent applic ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Recombinant Botulinum Neurotoxin for Treatment of Spastic Disorders

    SBC: Cytodel, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Botulinum neurotoxin (BoNT) is the active ingredient in pharmaceutical products like Botox(R) (Allergan), which FDA has approved for therapeutic and aesthetic indications. Because of its inherent toxicity,the dose of BoNT required to treat spasticity disorders in large muscle groups is uncomfortably close to the toxic dose range. ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Metal ion-functionalized soluble nanopolymers: A new analytical platform for plas

    SBC: TYMORA ANALYTICAL OPERATIONS LLC            Topic: 300

    DESCRIPTION provided by applicant Mass spectrometry based proteomics is an emerging technology that has seen possible applications everywhere The technique can potentially use one drop of our blood to reveal onset and progress of diseases Current Randamp D using plasma serum proteome sample sets however is severely limited by the high complexity and dynamic range of protein concentrations ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Computer-based Prescription Opioid Abuse Prevention for Adolescents

    SBC: HEALTHSIM, INC.            Topic: R42

    DESCRIPTION provided by applicant Recreational use of prescription opioids among adolescents is a significant and growing public health concern and has been referred to as an emerging epidemic in the U S Although a number of science based interactive drug abuse prevention programs exist focused on preventing use of non prescription drugs among youth to our knowledge no science based inter ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Fluorescence Image-Guided Near Infrared (NIR) Photodynamic Therapy (PDT) Agent

    SBC: PHOTOLITEC LLC            Topic: 102

    DESCRIPTION provided by applicant Photolitecandapos s patented technology is focused on developing improved agents for tumor imaging image guided surgery and or photodynamic therapy PDT The proposed STTR proposal includes fluorescence image guided PDT a andquot See and Treatandquot approach The fluorescence imaging compound with long wavelength absorption near nm should be extremel ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II

    SBC: BITE TECHNOLOGIES, LLC            Topic: 300

    DESCRIPTION provided by applicant Self monitoring has been described as the andquot cornerstone of the behavioral treatment of obesityandquot Consistent self monitoring of energy intake is associated with improved dietary adherence and weight loss and maintenance The problem is that individuals are notoriously bad at self monitoring their intake and suffer from an underreporting bias The s ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a new approach to screening for language impairments

    SBC: PANTHER TECHNOLOGY            Topic: NIDCD

    DESCRIPTIONprovided by applicantThis Small Business Technology and TransferSTTRFast Track proposal focuses on the translation of innovative research protocols for diagnosing Specific Language ImpairmentSLIinto an innovativeeasy touse app based screener with high potential for private sector commercializationSLI is a form of language impairment with no known causewith a strong research baseBecause ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Development and in vitro validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government